Lexicon Pharmaceuticals | LXRX - Interest Expense On Debt


Lexicon Pharmaceuticals reported $2.03M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Abbott USD 297M 2M Sep/2026
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.06B 44.38M Sep/2026
Akebia Therapeutics 342.13M 7.53M Sep/2026
Alnylam Pharmaceuticals USD -84.37M 166.42M Sep/2026
AstraZeneca USD 371M 31M Sep/2026
BioMarin Pharmaceutical USD 55.63M 7.67M Sep/2026
Coherus Biosciences USD 2.25M 76K Dec/2025
Eli Lilly USD 316M 201.3M Sep/2026
Halozyme Therapeutics USD 6.04M 457K Sep/2026
Illumina USD 24M 0 Sep/2026
Insmed USD 20.41M 1.57M Sep/2026
Ironwood Pharmaceuticals USD 8.74M 506K Dec/2024
J&J USD 43M 25M Mar/2026
Lexicon Pharmaceuticals USD 2.03M 124K Dec/2025
MacroGenics USD 4.4M 493K Jun/2026
MannKind USD 10.58M 4.24M Sep/2026
Merck USD 525M 46M Jun/2026
Moderna USD 10.96B 527M Jun/2026
Novartis USD 468M 6M Sep/2026
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Puma Biotechnology USD 3.37M 11K Jun/2024
Sarepta Therapeutics USD 21.51M 205K Jun/2026
Thermo Fisher Scientific USD 417M 63M Sep/2026
Ultragenyx Pharmaceutical USD 20M 2M Sep/2026
United Therapeutics USD 2.9M 0 Sep/2026
Vanda Pharmaceuticals -1.37B 1.97B Dec/2025